ASP同位素公司与Isotopia宣布达成钆-160供应协议，以加速用于先进癌症治疗的铽-161生产ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

动脉网2025-06-02

PETACH TIKVA,佩塔提克瓦，Israel以色列,，June 2, 20252025年6月2日/PRNewswire/ -- ASP Isotopes Inc. (NASDAQ:/PRNewswire/ -- ASP Isotopes Inc.（纳斯达克：ASPI亚太安全合作理事会) and Isotopia Molecular Imaging Ltd. have entered into...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2540908763?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-02 15:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2540908763","market":"us","top_or_hot":-1,"title":"ASP同位素公司与Isotopia宣布达成钆-160供应协议，以加速用于先进癌症治疗的铽-161生产ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies","media":"动脉网","content":"<div>\n<p>PETACH TIKVA,佩塔提克瓦，Israel以色列,，June 2, 20252025年6月2日/PRNewswire/ -- ASP Isotopes Inc. (NASDAQ:/PRNewswire/ -- ASP Isotopes Inc.（纳斯达克：ASPI亚太安全合作理事会) and Isotopia Molecular Imaging Ltd. have entered into...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602152716950b4a53&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASP同位素公司与Isotopia宣布达成钆-160供应协议，以加速用于先进癌症治疗的铽-161生产ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASP同位素公司与Isotopia宣布达成钆-160供应协议，以加速用于先进癌症治疗的铽-161生产ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-02 15:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602152716950b4a53&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PETACH TIKVA,佩塔提克瓦，Israel以色列,，June 2, 20252025年6月2日/PRNewswire/ -- ASP Isotopes Inc. (NASDAQ:/PRNewswire/ -- ASP Isotopes Inc.（纳斯达克：ASPI亚太安全合作理事会) and Isotopia Molecular Imaging Ltd. have entered into...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602152716950b4a53&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4109","symbol_name":"特种化学制品","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602152716950b4a53&s=b","article_id":"2540908763","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602152716950b4a53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2540908763","pubTimestamp":1748847600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies.该合作伙伴关系解决了长期以来的Gd-160供应挑战，使Isotopia能够推进基于Tb-161的前列腺癌、神经内分泌肿瘤和其他恶性肿瘤疗法的发展。过去两年中，Isotopia持续生产镥-177，并为其临床试验维持每周一次的铽-161生产。Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-e","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4109":"特种化学制品","AAQC":"Accelerate Acquisition Corp","ASPI":"ASP Isotopes Inc."},"translate_title":"ASP Isotopes and Isotopia announce gadolinium-160 supply agreement to accelerate terbium-161 production for advanced cancer therapy ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASPI":0.9,"AAQC":1},"content_text":"PETACH TIKVA,佩塔提克瓦，Israel以色列,，June 2, 20252025年6月2日/PRNewswire/ -- ASP Isotopes Inc. (NASDAQ:/PRNewswire/ -- ASP Isotopes Inc.（纳斯达克：ASPI亚太安全合作理事会) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.）和Isotopia分子影像有限公司达成了战略协议，以确保获得生产铽-161（Tb-161）所需的关键前体同位素钆-160（Gd-160）。铽-161是一种新兴的医用同位素，在靶向放射治疗领域具有重大潜力。This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies.该合作伙伴关系解决了长期以来的Gd-160供应挑战，使Isotopia能够推进基于Tb-161的前列腺癌、神经内分泌肿瘤和其他恶性肿瘤疗法的发展。Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161.根据协议，ASP同位素公司将利用其专有的量子富集技术，向Isotopia提供富集的钆-160（Gd-160），这是一种制造铽-161（Tb-161）所必需的稳定同位素。The collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia's proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years. .该合作结合了ASP Isotopes在大规模同位素富集方面的专业知识——此前通过生产镱-176（Yb-176）得到了证明——以及Isotopia在商业规模医疗同位素生产中的成熟能力。过去两年中，Isotopia持续生产镥-177（Lu-177），并为其临床试验维持每周一次的铽-161（Tb-161）生产。Paul Mann保罗·曼, CEO，首席执行官of ASP IsotopesASP同位素, emphasized the agreement's significance: 'By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms.' .强调了该协议的重要性：“通过供应钆-160，我们正在消除铽-161疗法开发中的一个主要瓶颈。我们对浓缩技术的投资使我们能够支持放射性药物行业对稳定同位素日益增长的需求。这一合作加快了铽-161临床应用的进程，这可能重新定义癌症治疗模式。”Dr.博士Eli Shalom以利·沙洛姆, CEO of Isotopia，Isotopia首席执行官, highlighted Tb-161's therapeutic advantages: 'Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization.，突出了Tb-161的治疗优势：“Tb-161的双重作用机制，包括俄歇电子发射，能够精准靶向微小转移灶，同时将对健康组织的损害降至最低。此次合作确保了Gd-160供应链的可靠性，使我们能够扩大生产规模，并推动我们的Tb-161标记药物候选物迈向商业化。”We produce in our site in .我们在我们的站点生产。Israel以色列and shortly the production will start in our second site in很快，我们第二个地点的生产将开始Indianapolis印第安纳波利斯in the US.'在美国。Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field's shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumor-seeking molecules. .Tb-161的俄歇电子在癌细胞中诱导双链DNA断裂，相比Lu-177和α发射同位素具有潜在优势。这种精准性符合肿瘤学领域向靶向放射治疗的转变，可提高疗效并减少副作用。该协议正值全球对放射性药物的兴趣激增之际，其背后推动力是这些药物能够通过靶向肿瘤的分子提供局部放射治疗。About ASP Isotopes Inc.关于ASP同位素公司ASP Isotopes Inc. specializes in advanced isotope separation technologies, including its proprietary Aerodynamic Separation Process and Quantum Enrichment, which produce stable isotopes without radioactive waste. The company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.ASP同位素公司专注于先进的同位素分离技术，包括其专有的空气动力分离工艺和量子富集技术，这些技术可以在不产生放射性废料的情况下生产稳定同位素。该公司最初的重心是为医疗保健和技术行业生产和商业化高丰度同位素。The Company has isotope enrichment facilities in .公司拥有位于 的同位素浓缩设施。Pretoria, South Africa南非比勒陀利亚. For more information, please visit欲了解更多信息，请访问www.aspisotopes.comwww.aspisotopes.com.。About Isotopia Molecular Imaging Ltd.关于Isotopia分子影像有限公司Isotopia is a global leader in medical isotope production, with facilities inIsotopia 是医疗同位素生产的全球领导者，在以下地区拥有设施：Israel以色列,，Europe欧洲, and the U.S. Its integrated platform includes cyclotrons, Lu-177 and Tb-161 production sites, and sterile manufacturing capabilities. The company collaborates with researchers and clinicians to develop novel radiopharmaceuticals for diagnostics and targeted therapy.，以及美国。其集成平台包括回旋加速器、Lu-177 和 Tb-161 生产基地以及无菌制造能力。该公司与研究人员和临床医生合作，开发用于诊断和靶向治疗的新型放射性药物。This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide.这一合作伙伴关系使两家公司处于放射性药物革命的前沿，有望为全球癌症患者扩展治疗选择。Contact:联系：eshalom@isotopia-global.com艾沙洛姆@同位素全球.comLogo -标志 -https://mma.prnewswire.com/media/2659964/Isotopia_Logo.jpghttps://mma.prnewswire.com/media/2659964/Isotopia_Logo.jpgWANT YOUR COMPANY'S NEWS想要你公司的新闻吗FEATURED ON PRNEWSWIRE.COM?荣登PRNEWSWIRE.COM？440k+44万+Newsrooms &新闻编辑室 &Influencers影响者9k+9k+Digital Media数字媒体Outlets插座270k+27万+Journalists记者Opted In已选择加入GET STARTED开始使用","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2540908763","isCrawlerRequest":true}